MedTrace Logo

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

NCT00330499 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2017-07-12

No results posted yet for this study

Summary

The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.

Conditions

  • Transitional Cell Carcinoma of Urinary Bladder

Interventions

DRUG

Cisplatin

Weekly Cisplatin 35mg/m2 x 6 doses, IV administration

RADIATION

External beam radiation treatment

64Gy reference dose in 32 fractions over 6.5 weeks

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • Kumar Gogna · Mater Centre - South Brisbane

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330499 on ClinicalTrials.gov